Biomet is to be the exclusive distributor of Bonesupport’s proprietary Cerament™ bone void filler in an agreement which spans U.S. and Canada.
Biomet has an exclusive, binding offer of $280M on the table for J&J’s DePuy Trauma division. The deal is thought to represent J&J’s concession, extracted from the leviathan by an EU commission, in order to ratify its $21Bn takeover of Synthes.
Biomet is paying out a lot of money to settle it’s bribery allegations case with US SEC and Justice Department.
Signature™ Personalized Patient Care* System with the Oxford® Partial Knee Provides Enhanced Surgery Planning and Procedure Performance
Biomet, Inc., has announced FDA clearance of two new products; the E1® humeral bearing for use with the Comprehensive® Reverse Shoulder System, and the Comprehensive® Segmental Revision System.
Biomet Inc’s second quarter preliminary net sales reports have been published and show a continuation of the tendency for highest growth levels to be coming from ex-USA and ex-Eu sources.
Biomet celebrates the 35th anniversary of the Oxford Partial Knee System
Biomet reports Q1(2012) overall sales up 3.7%, but losses are up 120% during the three months ended August 31.
Smith & Nephew Plc rose the most in almost eight months in London trading after four U.K. newspapers reported that traders were speculating the maker of artificial knees and hips may receive a takeover offer.
Biomet’s Sports Medicine business unit has received the 2011 Medical Design Excellence Award for the outstanding product design of its JuggerKnot™ Soft Anchor.
Biomet, Inc. announced today financial results for its second fiscal quarter ended November 30, 2008.